# Influenza Vaccine Trivalent Inactivated Adjuvanted: FLUAD® 2017–2018

**Revision Date:** June 15, 2017

Please consult the Product Monograph for further information about the vaccine.

<table>
<thead>
<tr>
<th><strong>FLUAD® 2017–2018</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturer</strong></td>
</tr>
<tr>
<td><strong>Off-license use</strong></td>
</tr>
</tbody>
</table>
| **Influenza strains for 2016-2017 season** | A/Michigan/45/2015 (H1N1)pdm09-like virus\(^1,2\)  
A/Hong Kong/4801/2014 (H3N2)-like virus\(^1,2\)  
B/Brisbane/60/2008-like virus\(^1,2\) |
| **Indications for use of provincially funded vaccine** | Albertans 65 years of age and older who are included in the Alberta Health Services Outreach Programs, as defined in the Alberta Influenza Immunization Policy.\(^6\) |
| **Use in individuals younger than 65 years of age** | Not recommended for individuals younger than 65 years of age.\(^1\) |
| **Dose**              | 0.5 mL |
| **Route**             | Intramuscular injection |
| **Schedule**          | 65 years of age and older:  
   - 1 dose |
| **Contraindications** |  
   - Known severe hypersensitivity to any component of FLUAD® with the exception of egg.\(^3\) (see Precautions below).  
   - Anaphylactic or other allergic reaction to a previous dose of influenza vaccine.\(^1\)  
   - Avoiding subsequent immunization of individuals known to have had Guillain-Barré Syndrome (GBS) within six weeks of a previous influenza immunization appears prudent at this time.\(^3\) However, the potential risk of GBS recurrence associated with influenza vaccine must be balanced against the risk of GBS associated with influenza infection itself and the other benefits of influenza immunization.\(^3\) The relative and attributable risks of GBS after seasonal influenza immunization are lower than those after influenza illness.\(^4\) |
| **Precautions**       |  
   - Egg-allergic individuals may be immunized against influenza using trivalent inactivated adjuvanted vaccine without a prior influenza vaccine skin test and with the full dose of vaccine, irrespective of a past severe reaction to egg.\(^3\) Egg-allergic vaccine recipients should be kept under observation for 30 minutes following the administration of inactivated influenza vaccine.  
   - Expert review of the risks and benefits of influenza immunization should be sought for individuals who previously experienced severe lower-respiratory symptoms (wheeze, chest tightness, dyspnea) within 24 hours of influenza immunization, an apparent significant allergic reaction to the vaccine or any other symptoms (e.g. throat constriction or dysphagia) that raise concern regarding the safety of re-immunization.\(^3\) This advice may be obtained from the local Medical Officer of Health or other experts in infectious disease, allergy/immunology and/or public health or any combination of these specialities.\(^3\) |
Alberta Health, Public Health and Compliance Division
Alberta Immunization Policy - Biological Products
Influenza Vaccine FLUAD®
June 15, 2017

• Individuals who have experienced oculorespiratory syndrome (ORS) including those with a severe presentation (bilateral red eyes, cough, sore throat, hoarseness, facial swelling) but without lower respiratory tract symptoms, may be safely re-immunized.³ Advise of an expert should be sought before immunizing individuals who experienced ORS with lower respiratory tract symptoms.³

• Although influenza vaccine can inhibit the clearance of warfarin and theophylline, clinical studies have not shown any adverse effects attributable to these drugs in people receiving influenza vaccine.³

Possible reactions

• Immunization with FLUAD® cannot cause influenza because the vaccine does not contain live virus.¹

• In clinical trials, the incidence of reported systemic reactions was generally slightly higher in FLUAD® than in the comparator group.¹

• Adverse events following immunization are generally mild or moderate and of limited duration.¹

Local:

• Injection site pain, erythema, swelling, induration and temperature at the injection site.

Systemic:

• Headache, fatigue, malaise, myalgia, chills, nausea, rash, sweating, arthralgia and fever.¹

• The following additional adverse events have been reported through post-market surveillance: Injection-site cellulitis-like reaction, extensive swelling of injected limb lasting more than one week, allergic reactions leading to shock, angioedema, vasculitis, thrombocytopenia, lymphadenopathy, muscular weakness, neuralgia, paraesthesia, convulsion, myelitis, neuritis, GBS, pruritus, urticaria and non-specific rash.¹

• Refer to: Adverse Events Following Immunization (AEFI), Policy for Alberta Immunization Providers.⁵

Pregnancy

FLUAD® is not recommended for pregnant women.

Lactation

FLUAD® is not recommended for breastfeeding women.

References


